Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).

MLA

Byrne, Barry J., et al. “Long-Term Safety and Efficacy of Cipaglucosidase Alfa plus Miglustat in Individuals Living with Pompe Disease: An Open-Label Phase I/II Study (ATB200-02).” Journal of Neurology, vol. 271, no. 4, Apr. 2024, pp. 1787–801. EBSCOhost, https://doi.org/10.1007/s00415-023-12096-0.

APA

Byrne, B. J., Schoser, B., Kishnani, P. S., Bratkovic, D., Clemens, P. R., Goker-Alpan, O., Ming, X., Roberts, M., Vorgerd, M., Sivakumar, K., van der Ploeg, A. T., Goldman, M., Wright, J., Holdbrook, F., Jain, V., Benjamin, E. R., Johnson, F., Das, S. S., Wasfi, Y., & Mozaffar, T. (2024). Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). Journal of Neurology, 271(4), 1787–1801. https://doi.org/10.1007/s00415-023-12096-0

Chicago

Byrne, Barry J, Benedikt Schoser, Priya S Kishnani, Drago Bratkovic, Paula R Clemens, Ozlem Goker-Alpan, Xue Ming, et al. 2024. “Long-Term Safety and Efficacy of Cipaglucosidase Alfa plus Miglustat in Individuals Living with Pompe Disease: An Open-Label Phase I/II Study (ATB200-02).” Journal of Neurology 271 (4): 1787–1801. doi:10.1007/s00415-023-12096-0.